Compositions and methods for enhancing the immunogenicity of antigens

Patent Citations (62)

Non-Patent Literature (363)

• Lasa et al, EMBO 16(7): 1531-40, Apr. 1997.Examiner
• Rechsteiner et al, TIBS 21: 267-271, Jul. 1996.Examiner
• Pan et al, Cancer Research 55: 4776-4779, Nov. 1995.Examiner
• Finn et al, Nature Reviews Immunology 3: 630-641, Aug. 2003.Examiner
• Attwood et al, The Babel of Bioinformatics, 2000, Science vol. 290 No. 5491: 471-473.Examiner
• Guzman, C.A. et al. (Jun. 1998). “Attenuated Listeria monocytogenes Carrier Strains can Deliver an HIV-1 gpl20 T Helper Epitope to MHO Class II-Restricted Human CD4+ T Cells,” Eur. J. Immunol. 28:1807-1814.Applicant
• Lebrun. M. at al. (Aug. 1998). “Internalin Must be on the Bacterial Surface to mediate Entry of Listerla monocytogenes Into Epithelial Cells,” Molecular Microbiology 21:579-592.Applicant
• Paglia, P. et al. (Jun. 1997). “The Defined Attenuated Listeria monocytogenes Ampl2 Mutant is an Effective Oral Vaccine Carrier to Trigger a Long-Lasting Immune Response Against a Mouse Fibrosarcoma,” Eur. J. Immunol. 27:1570-1575.Applicant
• Shen, H. et al. (Apr. 25, 1995). “Recombinant Listeria monocytogenes as a Live Vaccine Vehicle for the Induction of Protective Anti-Viral Cell-Mediated Immunity,” Proc. Natl. Acad Sci. USA 92: 3987-3991.Applicant
• Skoble, J. et al. (Aug. 7, 2000). “Three Regions within ActA Promote Arp2/3 Complex-mediated Actin Nucleation and Listeria monocytogenes Motility,” The Journal of cell Biology 150(3):527-537.Applicant
• Smith, G.A. et al. (Sep. 1995). “Asymmetric Distribution of the Listeria monocytogenes ActA Protein is Required and Sufficient to Direct Actin-Based Motility,” Molecular Microbiology 17:945-951.Applicant
• Welch, M.D. at al. (Jul. 3, 1998). “Interaction of Human Arp2/3 Complex and the Listeria monocytogenes ActA Protein in Actin Filament Nucleation,” Science 281:105-108; pa-998020.Applicant
• Jenson E. R. et al (1997) “Recombinant Listeria monocytogenes as a ilve vaccine vehicle and a probe for studying cell-mediated immunity” Immunological Review, vol. 158, 147-157.Applicant
• Adams et al. (1992) “Cre-lox recombination in Escherichia coli cells. Mechanistic differences from the in vitro reaction.” J. Mol. Biol. 226:661-673.Applicant
• Allison et al. (1997) “Cloning and characterization of a Prevotella rnelaninogenica hemolysin.” Infect Immun. 65,(7):2765-71.Applicant
• An et al. (1996) “A recombinant minigene vaccine containing a nonameric cytoxic-T-Lymphocyte epitope confers limited protection against Listeria monocytogenes infection” Infect Immun 64,(5):1685-1693.Applicant
• Anderson (1998) “Human gene therapy.” Nature. Apr. 30;392(6679 Suppl):25-30.Applicant
• Angelakopoulos et al. (2002) “Safety and shedding of an attenuated strain of Listeria monocytogenes with a deletion of actA/plcB in adult volunteers: a dose escalation study of oral inoculation.” Infect Immun. 70(7):3592-601.Applicant
• Attwood et al. (2000) “The Babel of Bioinformatics” Science 290(5491):471-473.Applicant
• Awwad (1989) “Cyclophosphamide-induced immunologically mediated regression of a cyclophosphamide-resistant murine tumor; a consequence of eliminating precursor L3T4+ suppressor T-cells.” Cancer Res. 49(7): 1649-1654.Applicant
• Barry et al. (1992) “Pathogenicity and immunogenicity of Listeria monocytogenes small-plaque mutants defective for intracellular growth and cell-to-cell spread.” Infection and Immunity 60 (4): 1625-32.Applicant
• Bast et al. (1975) “Antitumor activity of bacterial infection. II. effect of Listeria monocytogenes on growth of a guinea pig hepatoma.” J Natl. Cancer Inst., 54(3): 757-761.Applicant
• Bear (1986) “Tumor-specific suppressor T-cells which inhibit the in vitro generation of cytolytic T-cells from immune and early tumor-bearing host spleens.” Cancer Res. Apr;46(4 Pt 1):1805-12.Applicant
• Beatly, Dissertation Abstracts International, 2000, 61/10B:5224 Abstract Only.Applicant
• Bernhard et al. (2002) “Vaccination against the HER-2/neu oncogenic protein.” Endocrine-Related Cancer, 9:33-44.Applicant
• Bielecki et al. (1990) “Bacillus subtilis expressing a haemolysin gene from Listeria monocytogenes can grow in mammalian cells” Nature 354:175-176.Applicant
• Billington et al. (1997) “The Arcanobacterium (Actinomyces) pyogenes hemolysin, pyolysin, is a novel member of the thiol-activated cytolysin family.” J Bacteriol. Oct;179(19):6100-6.Applicant
• Bodmer et al. (1988) “Enhanced recognition of a modified peptide antigen by cytotoxic T cells specific for influenza nucleoprotein.” Cell 52: 253-258.Applicant
• Boon et al. (2006) “Human T cell responses against melanoma” Annu Rev Immunol. 24:175-208.Applicant
• Bourquin et al. (2000) “Myelin oligodendrocyte glycoprotein-DNA vaccination induces antibody-mediated autoaggression in experimental autoimmune encephalomyelitis” Eur J lmmunol 30:3663-3871.Applicant
• Boyer et al. (2005) “DNA prime Listeria boost induces a cellular immune response to SIV antigens in the rhesus macaque model that is capable of limited suppression of SIV239 viral replication.” Virology. Mar. 1;333(1)88-101.Applicant
• Brasseur et al. (1992) “Human gene MAGE-1, which codes for a tumor-rejection antigen, is expressed by some breast tumors. ”Int. J Cancer 52(5):839-841.Applicant
• Brockstedt el al. (2004) “Listeria-based cancer vaccines that segregate immunogenicity from toxicity.” Proc Natl Acad Sci USA. 101(38):13832-7.Applicant
• Bron et al. (2004) “Identification of Lactobacillus plantarum genes that are induced in the gastrointestinal tract of mice.” J Bacteriol. Sep;186(17):5721-9.Applicant
• Brown et al. (1988) “Site-specific integration in Saccharopolyspora erythraea and multisite integration in Streptomyces livictans of actinomycete plasmid pSE101.” J. Bacteriology 170: 2287-2295.Applicant
• Bruhn at al. (2005) “Characterization of anti-self CD8 T-cell responses stimulated by recombinant Listeria monocytogenes expressing the melanoma antigen 'TRP-2.” Vaccine, Jul. 21;23(33):4263-72.Applicant
• Brundage et al. (1993) “Expression and phosphorylation of the Listeria monocytogenes ActA protein in mammalian cells.” Proc. Natl. Acad. Sci. USA 90: 11890-11894.Applicant
• Bubert et al. (1997) “The Listeria monocytogenes iap gene as an indicator gene for the study of PrfA-dependent regulation.” Mol Gen Genet. Sep;256(1):54-62.Applicant
• Burnham (2003) “Bad bugs: good for cancer therapy?” Drug Discovery Today 8(2):54-55.Applicant
• Calendar et al. Poster presented at the ISOPOL Meeting 2001. http://64.233.169.104/search?q=cache:mA—uJpQsCrcJ:www.ma.uni-heidelberg.de/inst/imh/download/isopol.doc+Portnoy+Isopol+-2001&hl=en&ct=clnk&cd=3&,gl=us.Applicant
• Camilli at al. (1983) “Dual roles of plcA in Listeria monocytogenes pathogenesis.” Mol. Microbiol. 8:143-157.Applicant
• Carbone (1989) “Induction of ovalbumin-specific cytotoxic T cells by in vivo peptide immunization.” J Exp Med 169:603-612.Applicant
• Carbone (1990) “Class I-restricted processing and presentation of exogenous cell-associated antigen in vivo.” J Exp Med 171:377-387.Applicant
• Chamberlain et al. (2000) “Innovations and strategies for the development of anticancer vaccines.” Expert Opinion on Pharmacotherapy 1(4):603-614.Applicant
• Courvalin et al. (1995) “Gene transfer from bacteria to mammalian cells.” C R Acad Sci III. Dec;318(12):1207-12.Applicant
• Cunto-Amesty et al. (2003) “Strategies in cancer vaccines development.” Int J Parasitol. 33(5-6);597-613.Applicant
• Dakappagari et al. (2000) “Prevention of mammary tumors with a chimeric HER-2 B-cell epitope peptide vaccine.” Cancer Res. Jul. 15;60(14):3782-9.Applicant
• Darji et al. (2003) “Induction of immune responses by attenuated isogenic mutant strains of Listeria monocytogenes.” Vaccine 1;21 Suppl 2:S102-9.Applicant
• Darji et al. (1997) “Oral somatic transgene vaccination using attenuated S. typhimurium” Cell 91:765-775.Applicant
• Darji et al. (1995) “Hyperexpression of listeriolysin in the nonpathogenic species Listeria innocua and high yield purification.” J Biotechnol. Dec. 15;43(3):205-12.Applicant
• Darji et al. (1995) “Listeriolysin generates a route for the presentation of exogenous antigens by major histocompatibility complex class I.” Eur J immunol. Oct;25(10):2967-71.Applicant
• Darji et al. (1997) “TAP-dependent major histocompatibility complex class I presentation of soluble proteins using listeriolysin.” Eur J lmmunol. Jun;27(6):1353-9.Applicant
• Decatur et al. (2000) “A Pest-like sequence in Listeriolysin O essential for Listeria monocytogenes pathogenicity” Science 290(5493):992-995.Applicant
• Dermime et al. (2004) “Vaccine and antibody-directed T cell tumour immunotherapy.” Biochim Biophys Acta. 1704(1):11-35.Applicant
• Deshpande et al. (1997) “Isolation of a contact-dependent haemolysin from Mycobacterium tuberculosis.” J Med Microbiol. Mar;46(3):233-8.Applicant
• Dietrich et al. (1998) “Delivery of antigen-encoding plasmid DNA into the cytosol of macrophages by attenuated suicide Listeria monocytogenes” Nature BiotechnoIoy 15:181-185.Applicant
• Dietrich et al. (2001) “From evil to good: a cytolysin in vaccine development.” Trends Microbiol. Jan;9(1):23-8.Applicant
• Dramsi et al. (1995) “Entry of Listeria monocytogenes into hepatocytes requires expression of inIB, a surface protein of the intemalin multigene family.” Mol Microbiol. 16(2):251-61.Applicant
• Dunn et al. (1991) “Selective radiation resistance of immunologically induced T cells as the basis for irradiation-induced T-cell-mediated regression of immunogenic tumor.” J Leukoc Biol. 49(4): 388-396.Applicant
• Ebert et al. (1990) “Selective immunosuppressive action of a factor produced by colon cancer cells.” Cancer Res. 50(19):6158-6161.Applicant
• Ezzel (1995) “Cancer Vaccines: An Idea Whose Time Has Come?” J. NIH Res., 7:46-49.Applicant
• Falk et al. (1991) “Identification of naturally processed viral nonapeptides allows their quantification in infected cells and suggests an allele-specific T cell epitope forecast.” J Exp Med. 174(2):425-434.Applicant
• Finn et al. (2003) “Cancer vaccines: between the idea and the reality.” Nature Reviews Immunology 3:630-641.Applicant
• Frankel et al. (1995) “Induction of cell-mediated immune responses to human immunodeficiency virus type 1 Gag protein by using Listeria monocytogenes as a live vaccine vector” J. Immunol. 155:4775-4782.Applicant
• Frey (1993) “Rat adenocarcinoma 13762 expresses tumor rejection antigens but tumor-bearing animals exhibit tumor-specific Immunosuppression.” Clin Immunol Immunopathol. 69(2):223-233.Applicant
• Friedman et al. (2000) “Induction of human immunodeficiency virus (HIV)-specific CD8 T-cell responses by Listeria monocytogenes and a hyperattenuated Listeria strain engineered to express HIV antigens.” J. Virology 74 9987-9993.Applicant
• Fu et al. (1990) “Expansion of immunoregulatory macrophages by granulocyte-macrophage colony-stimulating factor derived from a murine mammary tumor.” Cancer Res. 50(2):227-234.Applicant
• Fujii (1987) “Significance of suppressor macrophages for immunosurveillance of tumor-bearing mice.” J Natl Cancer Inst. 78(3):509-517.Applicant
• Furukawa (1993) “Nude mouse metastatic models of human stomach cancer constructed using orthotopic implantation of histologically intact tissue.” Cancer Res. 53(5):1204-1208.Applicant
• Galen et al. (2001) “Can a ‘flawless’ live vector vaccine strain be engineered?” Trends Microbiol. 9(8):372-6.Applicant
• Gentschev et al. (1995) “Salmonella strain secreting active Listeriolysin changes its intracellular localization” Infect. lmmun. 63:4202-4205.Applicant
• Gentschev et al. (1996) “Development of antigen-delivery systems, based on the Escherichia coli hemolysin secreatiohn pathway.” Gene 179:133-140.Applicant
• Gilmore et al. (1989) “A Bacillus cereus cytolytic determinant, cereolysin AB., which comprises the phospholipase C and sphingomyelinase genes: nucleotide sequence and genetic linkage.” J Bacteriol. Feb;171(2):744-53.Applicant
• Glomski et al. (2002) “The Listeria monocytogenes hemolysin has an acidic pH optimum to compartmentalize activity and prevent damage to infected host cells.” J Cell Biol. Mar. 18;156(6)1029-38.Applicant
• Goebel et al. (1993) “Listeria monocytogenes—a model system for studying the pathomechanisms of an intracellular microorganism.” Zbl. Bakt. 278:334-347.Applicant
• Goossens et al. (1992) “Induction of protective CD8+ T lymphocytes by an attenuated Listeria monocytogenes actA mutant” Int Immunol. Dec;4(12):1413-8.Applicant
• Goossens et al. (1995) “Attenuated Listeria monocytogenes as a live vector for induction of CD8+ T cells in vivo: a study with the nucleoprotein of the lymphocytic choriomeningitis virus.” Int lmmunol. May;7(5):797-805.Applicant
• Gregory et al. (1997) “Internalin B promotes the replication of Listeria monocytogenes in mouse hepatocytes”. Infect lmmun. 65(12):5137-41.Applicant
• Gunn (2001) “Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16.” J Immunol. 167(11) 6471-6479.Applicant
• Gunn et al. (2002) “Recombinant Intra-cellular Bacteria as Carriers for Tumor Antigens.” In Vaccine Delivery Strategies, Chapter 14, Eds. Guido Dietrich and Werner Goebel, Horizon Scientific Press, UK.Applicant
• Gunn, Dissertation Abstracts International, 2001, 62/5B:2244 Abstract Only.Applicant
• Gunn et al. (2001) “Listeriolysin—a useful cytolysin.” Trends Microbiol.9(4):161-162.Applicant
• Harty et al. (1996) “Primary and secondary immune responses to Listeria monocytogenes.” Curr Opin Immunol. 8:526-530.Applicant
• Hassan et al. (2004) “Mesothelin: a new target for immunotherapy.” Clin Cancer Res. 10(12 Pt 1):3937-42.Applicant
• Hauf et al. (1997) “Listeria monocytogenes infection of P388D1 macrophages results in a biphasic NF-kappaB (RelA/p50) activation induced by lipoteichoic acid and bacterial phospholipases and mediated by IkappaBalpha and IkappaBbeta degradation.” Proc Natl Acad Sci U S A. Aug. 19;94(17):9394-9.Applicant
• Hess et al. (1995) “Listeria monocytogenes p60 supports host cell invasion by and in vivo survival of attenuated Salmonella typhimurium.” Infect Immun. May;63(5):2047-53.Applicant
• Hess et al. (1996) “Salmonella typhimurium aroA- infection in gene-targeted immunodeficient mice: major role of CD4+ TCR-alpha beta cells and IFN-gamma in bacterial clearance independent of intracellular location.” J Immunol. May 1:156(9):3321-6.Applicant
• Hess et al. (1996) “Superior efficacy of secreted over somatic antigen display in recombinant Salmonella vaccine induced protection against listeriosis” Proc. Nat. Acad. Sci. 93:1458-1463.Applicant
• Hess et al. (1997) “Protection against rnurine listeriosis by an attenuated recombinant Salmonella typhimurium vaccine strain that secretes the naturally somatic antigen superoxide dismutase.” Infect Immun. Apr;65(4):1286-92.Applicant
• Hess et al. (1998) “Mycobacterium bovis bacilli Calmette-Guerin strains secreting listeriolysin of Listeria monocytogenes” Proc. Natl. Acad. Sci. 95:5299-5304.Applicant
• Higgins et al. (1998) “Bacterial delivery of DNA evolves.” Nat Biotechnol. Feb:16(2):138-9.Applicant
• Hodgson (2000) “Generalized transduction of serotype 1/2 and serotype 4b strains of Listeria monocytogenes”. Mol Microbiol. 35(2):312-23.Applicant
• Hu et al. (2004) “Escherichia coli expressing recombinant antigen and listeriolysin O stimulate class I-restricted CD8+ T cells following uptake by human APC.” J. Immunology 172:1595-1601.Applicant
• Huang et al. (1994) “Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens.” Science 264961-965.Applicant
• Hussain et al. (2004) “CD4+CD25+ regulatory T cells that secrete TGFbeta and IL-10 are preferentially induced by a vaccine vector.” J lmmunother. Sep-Oct;27(5):339-46.Applicant
• Ikonomidis et al. (1994) Abstract E-90, Abstracts, 94th General Meeting of the American Society for Microbiology, May 23-27.Applicant
• Ikonomidis et al. (1994) “Delivery of a viral antigen to the class I processing and presentation oathway by Listeria monocytogenes” Journal of Medicine 180(6)2209-2218.Applicant
• Jensen (1997) “Recombinant Listeria monocytogenes vaccination eliminates papillomavirus-induced tumors and prevents papilloma formation from viral DNA” J Virol. 71(11):8467-8474.Applicant
• Jones et al. (1994) “Characterization of Listeria monocylogenes pathogenesis in a strain expressing perfringolysin O in place of listeriolysin O.” Infect. Immun. 62:5608-5613.Applicant
• Kaufman et al. (1999) “Impact of intracellular location of and antigen display by intracellular bacteria: implications for vaccine development” J Immunol. Lett, 65(1-2):81-84.Applicant
• Kerksiek (1999) “T cell responses to bacterial infection” Curr Opin. Immunol. 1(4):400-405.Applicant
• Kocks et al. (1992) “L. monocytogenes-induced actin assembly requires the ActA gene product” Cell 68(3):521-531.Applicant
• Kovacsovics-Bankowski et al. (1993) “Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages.” Proc. Natl. Acad. Sci USA 90:4942-4946.Applicant
• Lamikanra et al. (2001) “Regression of established human papillomavirus type 16 (HPV-16) immortalized tumors in vivo by vaccinia viruses expressing different forms of HPV-16 E7 correlates with enhanced CD8(+) T-cell responses that home to the tumor site.” J. Virology 75(20)9654-9664.Applicant
• Lampson et al. (1993) “Exploiting the lacZ reporter gene for quantitative analysis of disseminated tumor growth within the brain: use of the lacZ gene product as a tumor antigen, for evaluation of antigenic modulation, and to facilitate image analysis of tumor growth in situ.” Cancer Research 53:176-182.Applicant
• Lara-Tejero et al. (2004) “T cell responses to Listeria monocytogenes.” Curr Opin Microbiol. 7(1):45-50.Applicant
• Lasa et al. (1997) “Identification of two regions in the N-terminal domain of ActA involved in the actin comet tail formation by Listeria monocytogenes” EMBO 16(7)1531-40.Applicant
• Lauer et al. (2002) “Construction, characterization, and use of two Listeria monocytogenes site-specific phage integration vectors.” J. Bacteriology 184: 4177-4186.Applicant
• Lauer at al. ASM Meeting, Abstract 1999.Applicant
• LeaÅ et al. (1995) “A species-specific nucleotide sequence of Mycobacterium tuberculosis encodes a protein that exhibits hemolytic activity when expressed in Escherichia coli.” Infect lmmun. Nov;63(11):4301-6.Applicant
• Lee et al. (1991) “Construction of single-copy integration vectors for Staphylococcus aureus.” Gene 103:101-5.Applicant
• Lehner et al. (1996) “Processing and delivery of peptides presented by MHC class molecules.” Curr Opin Immunol. 8(1):59-67.Applicant
• Lejeune (1994) “Nitric oxide involvement in tumor-induced immunosuppression.” J Immunol. 152(10):5077-5083.Applicant
• Liau et al. (2002) “Tumor immunity within the central nervous system stimulated by recombinant Listeria monocytogenes vaccination.” Cancer Res. 62(8)2287-93.Applicant
• Lin et al. (1996) Treatment of established tumors with a novel vaccine that enhances Major Histocompatibility Class II presentation of tumor antigen Cancer Res. 56:21-26.Applicant
• Lin et al. (2002) “Oral vaccination with recombinant Listeria monocytogenes expressing human papillomavirus type 16 E7 can cause tumor growth in mice to regress.” Int J Cancer. Dec 20;102(6):629-37.Applicant
• Lingnau et al. (1995) “Expression of the Listeria monocytogenes EGD inIA and inIB genes, whose products mediate bacterial entry into tissue culture cell lines. by PrfA-dependent and—independent mechanisms.” Infect Immun. Oct;63(10):3896-903.Applicant
• Loeffler et al. (2006) “Comparison of different live vaccine strategies in vivo for delivery of protein antigen or antigen-encoding DNA and mRNA by virulence-attenuated Listeria monocytogenes.” Infect Immun. Jul;74(7):3946-57.Applicant
• Loessner et al. (1995) “Heterogeneous endolysins in Listeria monocytogenes bacteriophages: a new class of enzymes and evidence for conserved hotin genes within the siphoviral lysis cassettes.” Mol Microbiol. Jun;16(6):1231-41.Applicant
• Loessner et al. (2000) “Complete nucleotide sequence, molecular analysis and genome structure of bacteriophage A118 of Listeria monocytogenes: implications for phage evolution.” Molecular Microbiology 35(2):324-40.Applicant
• Makela et al. (1987) Hand Book of Experimental Immunology, vol. 1, chapter 3, pp. 3.1-3.13.Applicant
• Mandal et al. (2002) “Listeriolysin O-liposome-mediated cytosolic delivery of macromolecule antigen in vivo: enhancement of antigen-specific cytotoxic T lymphocyte frequency, activity, and tumor protection.” BBA 1563 7-17.Applicant
• Manjili et al. (2003) “HSP110-HER2/neu chaperone complex vaccine induces protective immunity against spontaneous mammary tumors in HER-2/neu transgenic mice.” J Immunol. Oct. 15;171(8):4054-61.Applicant
• Marquis et al. (1997) “Proteolytic pathways of activation and degradation of a bacterial phospholipase C during intracellular infection by Listeria monocytogenes.” J. Cell Biol. 137:1381-1392.Applicant
• Martin et al. (1986) “Nucleotide sequence of the tetM tetracycline resistance determinant of the streptococcal conjugative shuttle transposon Tn1545.” Nucleic Acid Res. 14:7047-7058.Applicant
• Marx et al. (2002) “Broad-host-range cre-lox system for antibiotic marker recycling in gram-negative bacteria.” Biotechniques. Nov;33(5):1062-7.Applicant
• McLaughlan et al. (1998) “Molecular characterization of an autolytic amidase of Listeria monocytogenes EGD.” Microbiology. May:144(Pt 5)1359-67.Applicant
• Mengaud et al. (1988) “Expression in Escherichia coli and sequence analysis of the Listeriolysin O determinant of Listeria monocytogenes” Infection and Immunity 56(4):766-772.Applicant
• Mikayama et al. (1993) “Molecular cloning and functional expression of a CDNA encoding gycosylation-inhibiting factor” Proc. Natl. Acad. Sci. USA 90:10056-10060.Applicant
• Mlynarova of al. (2002) “The promiscuity of heterospecific lox sites increases dramatically in the presence of palindromic DNA.” Gene. Aug. 21;296(1-2):129-37.Applicant
• Mollet et al. (1993) “Directed genomic integration, gene replacement, and integrative gene expression in Streptococcus thermophilus.” J. Bacteriology 175:4315-4324.Applicant
• Moriishi et al. (1998) “Sequence analysis of the actA gene of Listeria monocytogenes isolated from human” Microbiol. Immunol. 42(2):129-132.Applicant
• Ngo et al. (1994) The Protein Folding Problem and Tertiary Structure Prediction 492-495.Applicant
• Ochsenbein at al. (1999) “A comparison of T cell memory against the same antigen induced by virus versus intracellular bacteria.” Proc Natl Acad Sci U S A. Aug. 3;96(16):9293-8.Applicant
• Oscarsson et al. (1996) “Induction of haemolytic activity in Escherichia coli by the slyA gene product.” Mol Microbiol, Apr;20(1):191-9.Applicant
• Palmeros et al. (2000) “A family of removable cassettes designed to obtain antibiotic-resistance-free genomic modifications of Escherichia coli and other bacteria.” Gene. Apr. 18 ;247(1-2):255-64.Applicant
• Pan (1999) “Regression of established B16F10 melanoma with a recombinant Listeria monocytogenes vaccine.” Cancer Res 59(20):5264-5269.Applicant
• Pan et al. (1995) “A recombinant Listeria monocytogenes vaccine expressing a model tumour antigen protects mice against lethal tumour cell challenge and causes regression of established tumours”. Nature Med. 1:471-477.Applicant
• Pan et al. (1995) “Regression of established tumors in mice mediated by the oral administration of a recombinant Listeria monocytogenes vaccine” Cancer Res 55:4776-4779.Applicant
• Parida et al. (1998) “Internalin B is essential for adhesion and mediates the invasion of Listeria monocytogenes into human endothelial cells.” Mol Microbiol. Apr;28(1):81-93.Applicant
• Paul et at. (1989) “Fundamental Immunology”, Second Edition, Raven Press, 987-988.Applicant
• Peng et al. (2004) “The ability of two Listeria monocytogenes vaccines targeting human papillomavirus-16 E7 to induce an antitumor response correlates with myeloid dendritic cell function.” J. Immunol. 172:6030-6038.Applicant
• Penichet et al. (2001) “Antibody-cytokine fusion proteins for the therapy of cancer.” J. Immunological Methods 248:91-101.Applicant
• Peters at al. (2003) “Tailoring host immune responses to Listeria by manipulation of virulence genes—the interface between innate and acquired immunity.” FEMS Immunol Med Microbiol. Apr 1;35 3 :243-53.Applicant
• Pfeifer et al. (1993) “Phagocytic processing of bacterial antigens for class I MHC presentation to T cells.” Nature. Jan 28;361(6410);359-62.Applicant
• Pupa et al. (2001) “Prevention of spontaneous neu-expressing mammary tumor development in mice transgenic for rat proto-neu by DNA vaccination.” Gene Ther. Jan;8(1):75-9.Applicant
• Quenee et al. (2005) “Combined sacB-based negative selection and cre-lox antibiotic marker recycling for efficient gene deletion in Pseudomonas aeruginosa.” Biotechniques. Jan;38(1):63-7.Applicant
• Radford et al. (2002) “A recombinant E. coli vaccine to promote MHC class I-dependent antigen presentation: application to cancer immunotherapy.” Gene Therapy 9:1455-1463.Applicant
• Radford et al. (2003) “Recombinant E coli efficiently delivers antigen and maturation signals to human dendritic cells: presentation of MART1 to CD8+ T cells.” Int J. Cancer 105;811-819.Applicant
• Raveneau et al. (1992) “Reduced virulence of a Listeria monocytogenes phospholipase-deficient mutant obtained by transposon insertion into the zinc metalloprotease gene.” Infect. Immun. 60: 916-921.Applicant
• Realini et al. (1994) “KEKE motifs. Proposed roles in protein-protein association and presentation of peptides by MHC class I receptors” FEBS Letters 348:109-113.Applicant
• Rechsteiner et al. (1996) “Pest sequences and regulation by proteolysis” TIBS 21:267-271.Applicant
• Reiter at al. (1989) “Transfer RNA genes frequently serve as integration sites for prokaryotic genetic elements.” Nucleic Acids Research 17(5)1907-14.Applicant
• Renard et al. (2003) “HER-2 DNA and protein vaccines containing potent Th cell epitopes induce distinct protective and therapeutic antitumor responses in HER-2 transgenic mice.”' J Immuno. 171(3):1588-95.Applicant
• Repique (1992) “Immunosuppression derived from human B-lymphobiastoid and melanoma cell lines.” Cancer Invest. 10(3):201-208.Applicant
• Roden et al. (2004) “Vaccination to prevent and treat cervical cancer.” Hum Pathol 35(8):971-82.Applicant
• Rüssmann et al. (1998) “Delivery of epitopes by the Salmonella type III secretion system for vaccine development.” Science. Jul 24;281(5376):565-8.Applicant
• Safley et al. (1991) “Role of Listeriolysin-o (LLO) in the T Lymphocyte response to infection with Listeria monocytogenes” J Immunol. 146(10)13604-3616.Applicant
• Schafer et al. (1992) “Induction of a cellular immune response to a foreign antigen by a recombinant Listeria monocytogenes vaccine. ” J. Immunol. 149(1);53-59.Applicant
• Scheirlinck et al. (1989) “Integration and expression of alpha-amylase and endoglucanase genes in the Lactobacillus plantarum chromosome.” Appl Environ Microbiol 55(9):2130-7.Applicant
• Schmidt et al. (1995) “Molecular Analysis of the Plasmid-Encoded Hemolysin of Escherichia coli O157:H7 Strain EDL 933” Infection and Immunity. 63(3)1055-1061.Applicant
• Scortti et al. (2007) “The PrfA virulence regulon.” Microbes Infect. Aug;9(10):1196-207.Applicant
• Sevvell et al. (2004) “Regression of HPV-positive tumors treated with a new Listeria monocytogenes vaccine.” Arch Otolaryngol Head Neck Surg 130:92-97.Applicant
• Sewell et al. (2004) “Recombinant Listeria vaccines containing PEST sequences are potent immune adjuvants for the tumor-associated antigen human papillomavirus-16 E7.” Cancer Res. Dec. 15;64(24):8821-5.Applicant
• Shen et al. (1998) “Listeria monocytogenes as a probe to study cell-mediated immunity” Curr. Opin. Immunol. 10(4):450-458.Applicant
• Shen et al. (1998) “Compartmentalization of bacterial antigens: differential effects on priming of CD8 T cells and protective immunity.” Cell. Feb 20;92(4):535-45.Applicant
• Shetron-Rama et al. (2002) “Intracellular induction of Listeria monocytogenes actA expression.” Infect. Immun. 70:1087-1096.Applicant
• Shimizu et al. (1994) “Effects of CD4+ and CD8+ T cells in tumor-bearing mice on antibody production.” Cancer Immunol Immunother. 38(4)272-276.Applicant
• Singh et al. (2005) “Fusion to Listeriolysin O and delivery by Listeria mondcytogenes enhances the immunogenicity of HER-2/neu and reveals subdominant epitopes in the FVB/N mouse.” J Immunol. Sep. 15;175(6):3663-73.Applicant
• Sirard et al. (1997) “Intracytoplasmic delivery of Listeriolysin O by a vaccinal strain of Bacillus anthracis induces CD8-mediated protection against Listeria monocytogenes” J Immun. 159:4435-4443.Applicant
• Skolnick et al, (2000) “From genes to protein structure and function: novel applications of computational approached in the genomic era” Trends in Biotech. 18(1):34-39.Applicant
• Slifka et al. (1996) “Antiviral cytotoxic T-cell memory by vaccination with recombinant Listeria monocytogenes.” J. Virol. 70(5);2902-10.Applicant
• Smith et al. (1995) “The two distinct phospholipases C of Listeria monocytogenes have overlapping roles in escape from a vacuole and cell-to-cell spread.” Infect. Immun. 63 4231-4237.Applicant
• Souders et al. (2006) “In vivo bactofection: listeria can function as a DNA-cancer vaccine.” DNA Cell Biol. Mar;25(3):142-51.Applicant
• Stahl et al. (1984) “Replacement of the Bacillus subtilis subtilisin structural gene with an In vitro-derived deletion mutation.” J. Bacteriol 158:411-418.Applicant
• Starks et al. (2004) “Listeria monocytogenes as a vaccine vector: virulence attenuation or existing antivector immunity does not diminish therapeutic efficacy.” J. Immunology 173:420-427.Applicant
• Stitz et al. (1990) “Characterization and immunological properties of influenza A virus nucleoprotein (NP): cell-associated NP isolated from infected cells or viral NP expressed by vaccinia recombinant virus do not confer protection.” J Gen Virol. 71 (Pt 5):1169-1179.Applicant
• Strugnell et al. (1990) “Stable expression of foreign antigens from the chromosome of Salmonella typhimurium vaccine strains.” Gene 88:57-63.Applicant
• Stryer et al. (1998) Biochemistry, Third Edition, WH Freeman Company, New York, 31-33.Applicant
• Sun et al. (1990) “Isolation of Listeria monocytogenes small-plague mutants defective for intracellular growth and cell-to-cell spread.” Infect. lmmun. 58 3770-3778.Applicant
• Tanabe et al. (1999) “Induction of Protective T Cells against Listeria monocytogenes in Mice by Immunization with a Listeriolysin O-Negative Avirulent Strain of Bacteria and Liposome-Encapsulated Listeriolysin O” Infect. lmmun. 67(2):568-575.Applicant
• Tilney et al. (1989) “Actin filaments and the growth, movement, and spread of the intracellular bacterial parasite, Listeria monocytogenes.” J Cell Biol. Oct:109(4 Pt 1)1597-608.Applicant
• Vasil et al. (1982) “Cloning of a phosphate-regulated hemolysin gene (phospholipase C) from Pseudomonas aeruginosa.” J Bacterial. Oct;152(1):431-40.Applicant
• Vazquez-Boland et al. (1992) “Nucleotide sequence of the lecithinase operon of Listeria monocytogenes and possible role of lecithinase in cell-to-cell spread.” Infect. Immun. 60:219-230.Applicant
• Verch et al. (2004) “Listeria monocytogenes-based antibiotic resistance gene-free antigen delivery system applicable to other bacterial vectors and DNA vaccines.” Infect Immun. Nov;72(11):6418-25.Applicant
• Verma et al. (1995) “Delivery of class I and class II MHC-restricted T-cell epitopes of listeriolysin of Listeria monocytogenes by attenuated salmonella”, Vaccine 13(2)142-150.Applicant
• Walker et al. (1994) “Tumor growth alters T cell and macrophage production of and responsiveness to granulocyte-macrophage colony-stimulating factor: partial dysregulation through interleukin-10.” Cell Immunol. 154(1):342-357.Applicant
• Watson et al. (1991) “Splenic macrophages from tumor-bearing mice co-expressing MAC-1 and MAC-2 antigens exert immunoregulatory functions via two distinct mechanisms.” J Leukoc Biol.49(2): 126-138.Applicant
• Wei et al. (2005) “Listeria monocytogenes phosphatidylinositol-specific phospholipase C has evolved for virulence by greatly reduced activity on GPI anchors.” Proc. Natl Acad. Sci USA 102: 12927-12831.Applicant
• Weidt et al. (1994) “CD8+ T lymphocyte-mediated antiviral immunity in mice as a result of injection of recombinant viral proteins.” J Immunol. Sep 15;153(6):2554-61.Applicant
• Weiskirch et al. (1997) “Listeria monocytogenes: a potent vaccine vector for neoplastic and infectious disease.” Immunological Reviews 158:159-169.Applicant
• Wirth et al. (1986) “Highly efficient protoplast transformation system for Streptococcus faecalis and a new Escherichia coli-S. faecalis shuttle vector.” J Bactetiol. 165(3):831-6.Applicant
• Wu et al. (1995) “Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens” Cancer Res. 56:21-26.Applicant
• Young et al. (1992) “Tumor-derived cytokines induce bone marrow suppressor cells that mediate immunosuppression through transforming growth factor beta.” Cancer Immunol Immunother. 35(1): 14-18.Applicant
• Young et al. (1995) “Holins: form and function in bacteriophage lysis.” FEMS Microbiol Rev. Aug;17(1-2):191-205.Applicant
• Zhang at al. (1993) “Functional replacement of the hemolysin A transport signal by a different primary sequence.” Proc Natl Acad Sci U S A. May 1;90(9):4211-5.Applicant
• Angelov et al., “Therapeutic vaccine for acute and chronic motor neuron diseases: Implications for amyotrophic lateral sclerosis”, PNAS, Apr. 2003, vol. 100, No. 8, 4790-4795.Applicant
• Abachin et al., “Formation of D-alanyl-lipoteichoic acid is required for adhesion and virulence of Listeria monocytogenes”, Molecular Microbiology, 2002, 43(1), 1-14.Applicant
• Aggarwal et al., “Oral Salmonella: Malaria Circumsporozoite Recombinants Induce Specific CD8+ Cytotoxic T Cells”, J. Exp. Med. 1990, 172, 1083-1090.Applicant
• Alexander et al., “Characterization of an aromatic amino acid-dependent Listeria monocytogenes mutant: attenuation, persistance, and ability to induce protective immunity in mice”, infection and immunity, May 1993, p. 2245-2248.Applicant
• Amici et al., “DNA vaccination with full-length or truncated Neu induces protective immunity against the development of spontaneous mammary tumors in HER-2/neu transgenic mice”, Gene Therapy, 2000, 7, 703-706.Applicant
• Anido et al., “Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation”, The EMBO Journal, 2006, 25, 3234-3244.Applicant
• Bai et al., “Antigenic drift as a mechanism for tumor evasion of destruction by cytplytic T lymphocytes”, J. Clin. Invest., 2003, 111, 1487-1496.Applicant
• Bast et al., “Antitumor activity of bacterial infection, I. effect of listeria monocytogenes on growth of a murine fibrosarcoma”, J. Natl. Cancer Inst., 54:749-756, 1975.Applicant
• Baxeranis et al., Immunobiology of HER-2/neu oncoprotein and its potential application in cancer immunotherapy, Cancer Immunol. Immunother., 2004, 53, 166-175.Applicant
• Beattie et al., “Cloning and characterization of T-cell-reactive protein antigens from Listeria monocytogenes”, Infect. Immun., Sep. 1990; 58(9):2792-803.Applicant
• Beatty, “A dual role for IFN-gamma in resolving the balance between tumor progression and regression”, University of Pennsylvania, 2001, ii-xiii, 1-10.Applicant
• Beatty, Dissertation Abstracts International, 2000, 61/10B:5224 Abstract only.Applicant
• Bergmann et al., “The neu oncogene encodes an epidermal growth factor receptor-related protein”, Nature, vol. 319, Jan. 1986, 226-230.Applicant
• Biragyn et al., “Models for Lymphoma”, Current protocols in immunology, 2001, 20.6.1-20.6.30.Applicant
• Boon et al., “Tumor Antigens Recognized by T Lymphocytes”, Annu. Rev. Immunol. 1994,12, 337-365.Applicant
• Bouwer et al., “Acquired immunity to an intracellular pathogen: immunologic recognition of L. monocytogenes-infected cells”, Aug. 1997;158:137-46.Applicant
• Bouwer et al., “Cytotoxic-T-lymphocyte responses to epitopes of lsteriolysin O and p60 following infection with Listeria monocytogenes”, Infect. Immun., Jul. 1996; 64(7):2515-22.Applicant
• Bowie et al., Science 247:1306-1310, 1990.Applicant
• Bron et al., “Use of the air gene as a food-grade selection marker in lactic acid bacteria”, applied and environmental microbiology, Nov. 2002, vol. 68, No. 11, p. 5663-5670.Applicant
• Bruder et al., “Efficient induction of cytotoxic CD8+ T cells against exogenous proteins: establishment and charcterization of a T cell line specific for the membrane protein ActA of Listeria monocytogenes”, Eur. J. Immunol., Sep. 1998, 28(9):2630-9.Applicant
• Brunner et al., “Quantitative assay of the lytic action of immune lymphoid cells on cr-labelled allogeneic target cells in vitro; inhibition by isoantibody and by drugs”, Immunology, 1968, 14, 181-196.Applicant
• Camilli et al., “Listeria monocytogenes mutants lacking phosphatidylinositol-specific phospholipase C are avirulent”, J. Exp. Med., vol. 173, 751-754, Mar. 1991.Applicant
• Catic et al., “Introduction of protein or DNA delivered via recombinant Salmonella typhimurium into the major histocompatibility complex class I pesentation pathway of macrophages”, Microbes Infect., Feb. 1999, 1(2):113-21.Applicant
• Chazin et al., “Transformation mediated by the human HER-2 gene independent of the epidermal growth factor receptor”, Oncogene, 1992, 7, 1859-1866.Applicant
• Cheever et al., “T-Cell Immunity to Oncogeneic Proteins Including Mutated RAS and Chimeric BCR-ABL”, Ann. N.Y. Acad. Sci. 1993, 690:101-112 .Applicant
• Chen et al., “DNA Vaccines Encoding Full-Length or Truncated Neu Induce Protective Immunity against Neu-expressing Mammary Tumors”, Cancer Research 58, 1965-1971, May 1, 1998.Applicant
• Cho et al., “Structure of the extracellular region of HER2 alone and in complex with the herceptin Fab”, Nature, vol. 421, Feb. 2003, 756-760.Applicant
• Ciurea et al., “Viral presistence in vivo through selection of neutralizing antibody-escape variants”, PNAS, Mar. 2000, vol. 97, No. 6, 2749-2754.Applicant
• Cohen, J. Science 262:841-843.Applicant
• Concetti et al., “Autoantibody to P185erbB2/neu oncoprotein by vaccination with xenogenic DNA”, Cancer Immunol. Immunother., 1996, 43, 307-315.Applicant
• Coussens et al., “Tyrosine kinase receptor with extansive homology to EGF receptor shares chromosomal location with neu oncogene”, Sceince, vol. 230, 1132-1139, Dec. 1985.Applicant
• Darji et al., “Antigen-specific T cell receptor antagonism by antigen-presenting cells treated with the hemolysin of Lestria monocytogenes: a novel type of immune escape”, Eur. J. Immunol., Jul. 1997; 27(7):1696-703.Applicant
• Darji et al., “T-cell anergy induced by antigen presenting cells treated with the hemolysin of Listeria monocytogenes”, Immunol. Lett., Jun. 1997; 57(1-3):33-7.Applicant
• Darji et al., “The role of the bacterial membrane protein ActA in immunity and protection against Listeria monocytogenes”, J. Immunol., Sep. 1, 1998; 161(5):2414-20.Applicant
• Di Carlo et al., “Inhibition of Mammary Carcinogenesis by systemic interleukin 12 or P185neu DNA vaccination in HER-2/neu transgenic BALB\c mice”, Clinical Cancer Research, Mar. 2001, vol. 7, 830s-837s.Applicant
• Disis et al., “Effect of dose on Immune Response in Patients vaccinated with an HER-2/neu Intracellular Domain Protein-Based vaccine”, Journal of Clinical Oncology, vol. 22, No. 10, May 2004, 1916-1925.Applicant
• Disis et al., “Generation of T-cell Immunity to the HER-2/neu Protein After Active Immunization with HER-2/neu Peptide-Based Vaccines”, J. Clin. Oncol. 20:2624-2632, 2002.Applicant
• Disis et al., “HER-2/neu protein:A target for antigen-specific immunotherapy of Human Cancer”, Adv Cancer Res 71: 373-371, 1997.Applicant
• Disis et al., “Immunity to the HER-2/neu oncogenic protein”, Ciba Found. Symp. 1994 187:198-211.Applicant
• Disis et al., “Peptide-Based, but not whole protein, vaccines elicit immunity to HER-2/neu, an oncogenic self-protein”, The Journal of Immunology, 1996, 156:3151-3158.Applicant
• Doling et al., “Cytotoxic T-lymphocyte epitopes fused to anthrax toxin induce protective antiviral immunity”, Infect. Immun., Jul. 1999, 67(7):3290-6.Applicant
• Dumitrescu et al., “Understanding breast cancer risk—where do we stand in 2005?”, J. Cell. Mol. Med., vol. 9, No. 1, 2005, pp. 208-221.Applicant
• Dunn at al., “A critical function for type I interferons in cancer immunoediting”, vol. 6, No. 7, Jul. 2005, Nature Immunology, 722-729.Applicant
• Dunn et al., “Cancer immunoediting from immunosurveillance to tumor escape”, Nature Immunology, vol. 3, No. 11, Nov. 2002. 991-998.Applicant
• Dunn et al., “Interferon-γ and cancer Immunoediting”, Immunologic Research, 2005, 32/1-3: 231-245.Applicant
• Dunn, “The Immunobiology of cancer Immunosurveillance and Immunoediting”, Immunity, Aug. 2004, vol. 21, 137-148.Applicant
• Ercolini et al., “Recruitment of latent pools of high-avidity CD8+ T cells to the antitumor immune response”, JEM, vol. 201, No. 10, May 2005, 1591-1602.Applicant
• Esserman et al., “Vaccination with the extracellular domain of P185heu prevents mammary tumor development in neu transgenic mice”, Cancer Immunol. Immunother., 1999, 47, 337-342.Applicant
• Fields, “Preparation of antipeptide antibodies- Introduction to peptide synthesis”, Current Protocols in Molecular Biology, 2002, 11.15.1-11.15.9.Applicant
• Finn et al., MUC-1 Epithelial Tumor Mucin-Based Immunity and Cancer Vaccines, Immuno. Rev. 1995, 145:61-89.Applicant
• Foy et al, “Vaccination with HER-2/neu DNA or protein subunits protects against growth of HER-2/neu—expressing murine tumor”, Vaccine, 19, 2001, 2598-2606.Applicant
• Freshney, “Cluture of animal cells- a manual of basic technique”, Chapter 1, Second Edition, 1983, 1-6.Applicant
• Gallo et al., “Xenogeneic immunization in mice using HER2 DNA delivered by an adenoviral vector”, Int. J. Cancer, 113, 67-77, 2005.Applicant
• Gansbacher et al., “Interleukin 2 Gene Transfer into Tumor Cells Abrogates Tumorigenicity and Induces Protective Immunity”, J. Exp. Med. 1990, 172, 1217-1224.Applicant
• Garay-Malpartida et al., “Caspredictor: a new computer-based tool for caspase substrate prediction”, Bioinformatics, vol. 21, suppl. 1, 2005, p. 169-176.Applicant
• Garcia-Lora et al., “MHC class I-deficient metastatic tumor variants immunoselected by T lymphocytes originate from the corrdinated downregulatio of Apm components”, Int. J. Cancer, 106, 521-527, 2003.Applicant
• Gergory et al., 1997, “Internalin B promotes the replication of Listeria monocytogenes in mouse hepatocytes”, Infect. lmmun. 65(12):5137-41.Applicant
• Gillespie et al., “The potential of melanoma antigen expression in cancer therapy”, Cancer Treat. Rev. 1999, 25(4):219-27.Applicant
• Glenting et al., “A plasmid selection system in lactococcus lactis and its use for gene expression in L lactis and Iluman kidney fibroblasts”, Applied and environmental microbiology, Oct. 2002, vol. 68, No. 10, p. 5051-5056.Applicant
• Golsteyn et al., J. Cell Sci. 110:1893-1906, 1997.Applicant
• Golumbek et al., “Treatment of Established Renal Cancer by Tumor Cells Engineered to Secrete Interleukin-4”, Science 1991, 254, 713-716.Applicant
• Gritzapis et al., “Vaccination with Human HER-2/neu (435-443) CTL peptide induces effective antitumor immunity against HER-2/neu -Expressing tumor cells in vivo”, Cancer res., 66, May 10, 2006, 5452-5460.Applicant
• Gunn, “Recombinant Listeria monocytogenes as a tumor therapeutic”, University of Pennsylvania, 2001, ii-xiii, 1-10.Applicant
• Guy et al., “Expression of the neu proto oncogene in the mammary epithelium of transgenic mice induces metastatic disease”, Proc. Natl. Acad. Sci. USA, Nov. 1992, vol. 89, pp. 10578-10582.Applicant
• Harris et al., “Molecular Basis for Hetrogeneity of the Human P53 protein”, Molecular and Cellular Biology, Dec. 1986, vol. 6, No. 12, p. 4650-4656.Applicant
• Harty et al., “CD8 T lymphocytes specific for the secreted p60 antigen protect against Listeria monocytogenes infection”, J. Immunol., May 1, 1995; 154(9):4642-50.Applicant
• Hess et al., “Live antigen carriers as tools for improved anti-tuberculosis vaccines”, FEMS Immunol. Med. Microbiol., Feb. 1999, 23(2), 165-73.Applicant
• Higgins et al., “Delivery of protein to the cytosol of macrophages using Escherichia coli K-12”, Mol. Microbiol., Mar, 1999, 31(6):1631-41.Applicant
• Hiltbold et al., “Mechanisms of processing and presentation of the antigens of Listeria monocytogenes”, Infect. Agents Dis., Oct. 1994: 2(5):314-23.Applicant
• Hiltbold et al., “The presentation of class I and class II epitopes of listeriolysin O is regulated by intracellular localization and by intrecellular localization and by intracellular localization and by intracellular spread of Listeria monocytogenes”, Aug. 1996; 157(3):1163-75.Applicant
• Hoogenboom et al., “By passing Immunisation—human antibodies from synthetic repertoires of germline VHgene segments rearranged in vitro”, J. Mol. Biol., 1992, 227, 381-388.Applicant
• Hueman et al., “Phase I clinical trial of a HER-2/neu peptide (E75) vaccine for the prevention of prostate—specific antigen recurrence in high-risk prostate cancer patients”, Clin. Cancer Res., 11(20), Oct. 2005, 7470-7479.Applicant
• Ikonomidis et al., “Influenza-specific immunity induced by recombinant Listeria monocytogenes vaccines”, vaccine, vol. 15, No. 4, pp. 433-440, 1997.Applicant
• Ikonomidis et al., ASM Las Vegas, the 94th general meeting of the american soceity for microbiology, May 23-27, 1994, Las Vegas convention center, Las Vages, Nevada, p. 29, 159, 662, 664.Applicant
• Kruisbeek, In Vivo Depletion of CD4- and CD8-specific T cells, Current Protocols in Immunology 4.1.1-4.1.5, 1991.Applicant
• Jensen et al., 1997, “Recombinant Listeria monocytogenes as a live vaccine vehicle and a probe for studying cell-mediated immunity”, Immunological Review 158:147-157.Applicant
• Kawashima et al., “The Multi-epitope Approach for Immunotherapy for Cancer: Identification of Several CTL Epitopes from Various Tumor-Associated Antigens Expressed on Solid Epithelial Tumors”, Hum. Immunol. 1998 59:1-14.Applicant
• Khong et al., “Identification of multiple antigens recognized by tumor-infiltrating lymphocytes from a single patient: Tumor escape by antigen loss and loss of MHC expression”, J. Immunother., 2004, 27, 184-190.Applicant
• King et al., “Amplification of a Novel v-erbB-related gene in a human mammary carcinoma”, Sceince, Sep. 1985, vol. 229, 974-976.Applicant
• Kohler et al., “Expression of the iap gene coding for protein p60 of Listeria monocytogenes is controlled on the posttranseriptional level”, Journal of Bacteriology, Aug. 1991, vol. 173, No. 15, p. 4668-4674.Applicant
• Kumer et al., PNAS. 87:1337-1341, 1990.Applicant
• Knutson et al., “neu Antigen Negative Variants can be generated after neu-specific antibody therapy in neu transgenic mice”, Cancer Research 64, Feb. 2004, 1146-1151.Applicant
• Knutson et al., The Journal of Clinical Investigation, 107:477-484,2001.Applicant
• Kyte et al., “A simple method for displaying the hydropathic character of a protein”, J. Mol. Biol., 1982, 157, 105-132.Applicant
• Lacey et al., “Phase IIa safety and immunogenicity of a therapeutic vaccine, TA-GW, in persons with genital warts”, The Journal of Infectious Diseases, 1999, 179:612-8.Applicant
• Lauer et al., Molecular Microbiology 42(5):1163-1177, 2001.Applicant
• Lee et al., “Delivery of macromolecules into cytosol using liposomes containing hemolysin from Listeria monocytogenes”, J. Biol. Chem., Mar. 29, 1996; 271(13):7249-52.Applicant
• Lee et al., “The murine MHC class I genes, H-2D and H-2L, and two genes reported to encode tumor-specific antigens”, J. Exp. Med., Nov. 1988, vol. 168, 1719-1739.Applicant
• Leitner et al., “DNA and RNA-based vaccines: prinicples, progress and prospects”, Vaccine, Dec. 1999, 18(9-10):765-777.Applicant
• Lipford et al., “Vaccination with immunodominant peptides encapsulated in Quil A-containing liposomes induces peptide-specific primary CD8+ cytotoxic T cells”, Vaccine, Jan. 1994; 12(1):73-80.Applicant
• Liu, “Vaccine developments”, Nature medicine vaccine supplement. May 1998, vol. 4, No. 5, 515-519.Applicant
• Marks et al., “By-Passing Immunization human antibodies from V-gene libraries displayed on phage”, J. Mol. Biol. 1991, 222, 581-597.Applicant
• Mata et al., “Evalution of a recombinant Listeria monocytogenes expressing an HIV protein that protects mice against viral challenge”, Vaccine, 19, 2001, 1435-1445.Applicant
• Mazzaccaro et al., “Major histocompatibility Class I presentation of soluble antigen facilitated by Mycobacterium tuberculosis infection”, Proc. Natl. Acad. Sci. USA; Oct. 15, 1996; 93(21):11786-91.Applicant
• McCarty et al., “Targeting p53 for Adoptive T-Cell Immunotherapy”, Cancer Research 1998, 15:58 2601-5.Applicant
• McKaig et al., “Human Papillomavirus and Head and Neck Cancer: Epidemiology and Molecular Biology”, Head Neck 1998, 20 (3):250-65.Applicant
• Menguad et al., “Expression in Escherichia coli and sequence analysis of the listeriolysin O determinant of Listeria monocytogenes”, Infect. Immun., vol. 56, No. 4, 766-772, 1988.Applicant
• Miller et al., “Targeted vectors for gene therapy”, the FASB Journal, Feb. 1995, vol. 9, p. 190-199.Applicant
• Muller, “Expression of activated oncogenes in the murine mammary gland: transgenic models for human breast cancer”, Cancer and Metastasis Reviews, 10:217-227, 1991.Applicant
• Murali et al., “Structural analysis of P185C-neu and epidermal growth factor receptor tyrosine kinases: oligomerization of kinase domains”, Proc. Natl. Acad. Sci. USA, vol. 93, pp. 6252-6257, Jun. 1996, Biochemistry.Applicant
• Naz et al., “Novel human prostate-specific cDNA: molecular cloning, expression, and immunobiology of the recombinant protein”, Biochemical and Biophysical Research Communications 297, 2002, 1075-1084.Applicant
• Neeson et al., “A DNA prime-oral listeria boost vaccine in rhesus macaques induces a SIV-specific CD8 T cell mucosal response characterized by high levels of α4β7 integrin and an effector memory phenotype”, Virology, Oct. 2006, 354(2), 299-315.Applicant
• Neeson et al., “Listeriolysin O is an improved protein carrier for lymphoma immunoglobulin idiotype and provides systemic protection against 38c/3 lymphoma”, Cancer Immunol. Immunother., 2007, 13 pages.Applicant
• Nielsen et al., “Peptide nucleic acids as therapeutic agents”, Nucleic acids, p. 353-357.Applicant
• Pagano, J.S., “Epstein-Barr Virus: The First Human Tumor Virus and its Role in Cancer”, Proc. Assoc. Am. Physicians 1999 111(6):573-80.Applicant
• Pardoll, “Cancer Vaccines”, Nature medicine vaccine supplement, May 1998, vol. 4, No. 5, 525-531.Applicant
• Paterson et al., “Recombinant Listeria monocytogenes cancer vaccines”, Curr Opin Struct Biol 9(3): 353-357, Jun. 1997.Applicant
• Paterson et al., Proceedings of the American Association for Cancer Research, Mar. 2000, 41:890, abstract # S25.Applicant
• Paterson, Immunogenic Research, 27(2-3):451-462, Jun. 2003.Applicant
• Piechocki et al., “Complementary Antitumor Immunity Induced by Plasmid DNA Encoding Secreted and Cytoplasmic Human ErbB-2”, The Journal of Immunology, 2001, 167:3367-3374.Applicant
• Pilgrim et al., “Bactofection of mammalian cells by Listeria monocytogenes: improvement and mechanism of DNA delivery”, Gene Therapy, 2003, 10, 2036-2045.Applicant
• Pilon et al., “Vaccination with Crytoplasmic ErbB-2 DNA Protects Mice from Mammary Tumor Growth Without Anti-ErbB-2 Antibody”, The Journal of Immunology, 2001, 167:3201-3206.Applicant
• Pircher et al., “Viral escape by selection of cytotoxic T cell-resistant virus variants in vivo” Nature, vol. 346, Aug. 1990, 629-633.Applicant
• Pucci et al., “Straphylococcus hameolyticus contains two D-glutamic acid biosynthetic activities, a glutamate racemase and a D-amino acid transaminase”, Journal of Bacteriology, Jan. 1995, vol. 177, No. 2, p. 336-342.Applicant
• Punwaney et al., “Human Papillomavirus May be Common within Nasopharyngeal Carcinoma of Caucasian Americans: investigation of Epstein-Barr virus and human papillomavirus in Eastern and Western Nasopharyngeal Carcinoma using Ligation-Dependent polymerase chain reaction”, Head Neck 1999 21(1):21-9.Applicant
• Raffaghello et al., “Multiple defects of the antigen-processing machinery components in human neuroblastoma: immunotherapeutic implications”, Oncogene, 2005, 24, 4634-4644.Applicant
• Reilly et al., “HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice”, Cancer research 60, 3569-3576, Jul. 2000.Applicant
• Restifo et al., “Identification of Human Cancers Deficient in Antigen Processing”, J. Exp. Med. 1993, 177, 265-272.Applicant
• Restifo et al., “The promise of nucleic acid vaccines”, Gene Ther., Jan. 2000, 7(2): 89-92.Applicant
• Rogers et al., “Amino acid sequences common to rapidly degraded proteins: the PEST hypothesis”, Sceince, Reports, Oct. 1986, vol. 234, 364-368.Applicant
• Romero et al., “Coordinated downregulation of the anti gen presentation machinery and HLA class I/β2-microglobulin complex is responsible for HLA-ABC loss in bladder cancer”, Int. J. Cancer, 2005, 113, 605-610.Applicant
• Rovero et al., “DNA Vacciniation Against Rat Her-2/Neu p185 More Effectively Inhibits Carcinogenesis Than Transplantable Carcinomas in Transgenic BALB/c Mice”, The Journal of Immunology, 2000, 165:5133-5142.Applicant
• Scardino et al., “HER-2/neu and hTERT cryptic epitopes as Novel targets for broad spectrum tumor Immunotherapy”, The Journal of Immunology, 2002, 168:5900-5906.Applicant
• Schlom et al., “Cancer Vaccines:Moving Beyond Current Paradigms”, Clin. Cancer Res. 2007; 13(13), Jul. 1, 2007.Applicant
• Schmidt et al., 1995, “Molecular Analysis of the Plasmid-Encoded Hemolysin of Escherichia coli O157:H7 Strain EDL: 933”, Infection and Immunity, 63(3):1055-1061.Applicant
• Schneider et al., “Induction of pulmonary allergen-specific IgA responses or airway hyperresponsiveness in the absence of allergic lung disease following sensitization with. limiting doses of ovalbumin-alum”, Cellular Immunology, 212, 101-109, 2001.Applicant
• Schnupf et al., Cellular microbiology 8(2):353-364, 2006.Applicant
• Schwartz, “T cell anergy”, Annu. Rev. Immunol., 2003, 21, 305-34.Applicant
• Scortti et al., “The PrfA virulence regulon”, Microbes and Infection xx, 2007, 1-12.Applicant
• Seffernick et al., J. Bacteriol. 183(8):2405-10, Apr. 2001.Applicant
• Serth et al., “Increased Levels of Human Papillomavirus Type 16 DNA in a Subset of Prostate Cancers”, Cancer Res. 1999 15:59(4):823-5.Applicant
• Sewell et al., “Regression of HPV-positive tumors treated with a new listeria monocytogenes vaccine”, Arch Otolaryngol Head Neck Surg, Jan. 2004, vol. 130, 92-97.Applicant
• Shan et al.,“Recombinant Listeria monocytogenes as a Live Vaccine Vehicle for the Induction of Protective Anti-Viral Cell-Mediated Immunity”, Proc. Natl. Acad. Sci., USA, 92:3987-3991, Apr. 25, 1995.Applicant
• Shrikant et al., “CTLA-4 blockade reverses CD8+ T cell tolerance to tumor by a CD4+ T cell- and IL-2-dependent mechanism”, Immunity, Oct. 1999, vol. 11, 483-493.Applicant
• Silverman et al., Mol. Carcinog 3(6):379-86, 1990.Applicant
• Singh et al., “Structure-Based Design of a Potent, Selective and Irreversible Inhibitor of the Catalytic Domain of the erbB receptor subfamily of protein tyrosine kinases”, J. Med. Chem., 1997, 40, 1130-1135.Applicant
• Singh et al., “Vaccination Strategy Determines the emergence and dominanace of CD8+ T-cell epitopes in a FVB/N Rat HER-2/neu mouse model of breast cancer”, Cancer Res., 66, Aug. 15, 2006, 7748-7757.Applicant
• Stover et al., “New Use of BCG for Recombinant Vaccines”, Nature 1991, 351, 456-460.Applicant
• Strych et al., “Mutant analysis shows that alanine racemases from Pseudomonas aeruginosa and Escherichia coli are dimeric”, Journal of Bacteriology, Aug. 2002, p. 4321-4325.Applicant
• Szalay et al., “Presentation of Listeria monocytogenes antigens by major histocompatibility complex class I molecules to CD8 cytotoxic T lymphocytes independent of listeriolysin secretion and virulence”, Eur. J. Immunol., Jul. 1994; 24(7):1471-7.Applicant
• Teitelbaum et al., “Mycobacterial infection of macrophages results in membrane-permeable phagosomes”, Proc. Natl. Acad. Sci. USA, Dec. 1999; 96(26):15190-5.Applicant
• Thompson et al., “Pathogenicity and Immunogenicity of a listeria monocytogenes strain that requires D-alaninc for growth”, Infection and Immunity, Aug. 1998, vol. 66, No. 8, p. 3552-3561.Applicant
• Thull et al., “Recognition and management of hereditary breast cancer syndromes”, The Oncologist, 2004; 9:13-24.Applicant
• Townsend et al., “Tumor Rejection after Direct Costimulation of CD8+ T Cells by B7-Transfected Melanoma Cells”, Science 1993, 259, 368-370.Applicant
• Travis, “A Stimulating New Approach to Cancer Treatment”, Science 1993, 259, 310-311.Applicant
• Ulmanen et al., “Transcription and Translation of Foreign genes in Bacillus subtilis by the aid of a secretion vector”, Journal of Bacteriology, Apr. 1985, vol. 162, No. 1, p. 176-182.Applicant
• Uyttenhove et al., “Escape of mouse mastocytoma P815 after Nearly complete rejection is due to antigen-loss variants rather than immunosuppression”, J. Exp. Med., vol. 157, Mar. 1983,1040-1052.Applicant
• Vazquez et al., “Diffrerential regulation of la expression and antigen presentation by listeriolysin-producing versus non-producing strains of Listeria monocytogenes”, J. Leukoc Biol., May 1996; 59(5):683-90.Applicant
• Villanueva et al., “Listeriolysin is processed efficiently into an MHC class I-associated epitope in Listeria monocytogenes-infected cells”, J. Immunol., Dec. 1, 1995; 155(11):5227-33.Applicant
• Vines et al., “Identification and charcterization of nucleotide sequence difference in there virulence-associate genes of Listeria monocytogenes strains representing clinically important serotypes”, Current Microbiology, May 1998, vol. 36, No. 5, pp. 309-318.Applicant
• Vitiello et al., “Development of a Lipopeptide-based Therapeutic Vaccine to treat chronic HBV infection”, J. Clin. Invest., vol. 95, Jan. 1995, 341-349.Applicant
• Watson et al., “Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression correlates with a poor prognosis”, Int. J. Cancer, 2006, 118, 6-10.Applicant
• Wei et al., “Protection against mammary tumor growth by vaccination with full-length, modified human ErbB-2 DNA”, Int. J. Cancer, 81, 748-754, 1999.Applicant
• Wilson et al., “Transient expression of bacterial gene fragments in eukaryotic cells: implications for CD8(+) T cell epitope analysis”, J. Immunol. Methods, Feb. 2000, 234(1-2):137-47.Applicant
• Wingens et al., “Structural analysis of an epidermal growth factor / Transforming growth factor-α chimera with uniqe ErbB binding specificity”, The Journal of Biological Chemistry, vol. 278, No. 40, Issue of Oct. 3, pp. 39114-39123, 2003.Applicant
• Witkowski et al., Biochemistry 38(36):11643-50, Sep. 7, 1999.Applicant
• Wu et al., “Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens”, Proc. Natl. Acad. Sci. USA, 1995, 92:11671-5.Applicant
• Wunderlich et al., “Assays for T cell function: induction and measurement of cytotoxic T lymphocyte activity”, Current Protocols in Immunology, 1997, vol. 3, p. 3.11.1-3.11.20.Applicant
• Yaghmai et al., “Optimized regulation of gene expression using artificial transcription factors”, Molecular Therapy, Jun. 2002, vol. 5, No. 6, 685-694.Applicant
• Young et al., “Cloning and Expression of Influenza Virus Genes”, The Origin of Pandemic Influenza Viruses, W.G. Laver, eds., Elsevier Science Publishing Co., Inc., NY, 1983, p. 129.Applicant
• Zhang et al., “Selection of Tumor Antigens as Targets for. Immune Attack Using Immunohistochemistry: Protein Antigens”, Clin. Cancer Res. 1998 4:2669-2676.Applicant
• Zubair et al., In: Vaccines for human Papillomavirus Infection and Anogential Disease (ed. Robert W. Tindle); 1999, pp. 173-192.Applicant
• Zwickey et al., “Peptide epitopes from noncytosolic Listeria monocytogenes can be presented by major histocompatibiity complex class I molecules”, Infect. Immun., May 1996; 64(5):1870-2.Applicant
• Zvvickey et al.,“Antigen secreted from noncytosolic Listeria monocytogenes is processed by the classical MHC class I processing pathway”, J. Immunol, Jun. 1999, 162(11):6341-50.Applicant
• Hausen, “Papillomaviruses causing cancer: evasion from host cell control in early events in carinogenesis”, J. Nat. Cancer Inst., vol. 92, No. 9, 690-698.Applicant
• Jager et al., “Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4+ T lymphocytes of patients with NY-ESO-1 expressing melanoma”, J. Exp. Med., 2000, vol. 191, No. 4, 625-630.Applicant
• Peng et al., “Adjuvant properties of listeriolysin O protein in a DNA vaccination strategy”, Cancer Immunol. Immunother., (2007) 56: 797-806.Applicant